This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Voluntarily sign the informed consent form (ICF);
Male or female, ≥18 years old;
Survival duration more than 3 months;
ECOG score ≤ 1 point;
Participants with brainstem, meningeal, spinal metastases, orcompression; active central nervous system metastases;
Other malignancies diagnosed;
History of hypertensive crisis or hypertensive encephalopathy; presence of uncontrolled hypertension. History of arterial thrombosis or deep veinthrombosis within 6 months prior to enrollment;
Presence of any active autoimmune disease or a history of autoimmunedisease with an expected recurrence;